Benefits of Addressing Solubility Earlier in Development
Monday, January 23, 2017
Under pressure to minimize early development costs and timelines, many drug developers choose to put off addressing solubility challenges until Phase II or beyond. However, with up to 90% of today’s new molecular entities presenting as insoluble, not addressing solubility challenges early can result in even greater delays – and potentially compound failure. Patheon Solubility Enhancement Services approaches solubility a fundamentally different way by addressing low solubility earlier in development and identifying the technologies most likely to work before you get started. That helps avoid unintended outcomes and eliminate rework and worry later on.
Please complete the short form below to download this asset.